Frame

Colin Frame, Fall River CA

Patent application number	Description	Published
20080204335	TANK ANTENNA - An air tank for a self-contained breathing apparatus that incorporates a coil antenna for use in a magneto-inductive system. The coil antenna is formed as a part of the tank. The antenna is embedded within the sidewall of the air cylinder to form the air tank. The self-contained breathing apparatus may include a magneto-inductive device operatively connected to the coil antenna for conducting magneto-inductive communications. A microphone and speaker or headset may be included to facilitate voice communications over the magneto-inductive system.	08-28-2008

Patent application number	Description	Published
20100093769	COMPOUNDS - The present invention relates to compounds of formula (I)	04-15-2010
20100143350	COMBINATION OF A PURINE-BASED CDK INHIBITOR WITH A TYROSINE KINASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF PROLIFERATIVE DISORDERS - The present invention relates to combination comprising (i) an ErbB inhibitor; and (ii) a CDK inhibitor, or a pharmaceutically acceptable salt thereof, selected from: (a) roscovitine; (b) 3-{9-isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-pentan-2-ol; (c) 3-{9-isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-pentan-2-ol; and (d) (2R,3S-3-(6-((4,6-dimethylpyridin-3-ylmethylamino)-9-isopropyl-9H-purin-2-ylamino)pentan-2-ol.	06-10-2010

Patent application number	Description	Published
20090306098	COMBINATION OF ROSCOVITINE AND A HDCA INHIBITOR TO TREAT PROLIFERATIVE DISEASES - A first aspect of the invention relates to a combination comprising roscovitine, or a pharmaceutically acceptable salt thereof, and a HDAC inhibitor selected from sodium butyrate, or a prodrug thereof, suberoylanilide hydroxamic acid (SAHA), sodium valproate and trichostatin A (TSA). A second aspect of the invention relates to a pharmaceutical product comprising roscovitine, or a pharmaceutically acceptable salt thereof, and a HDAC inhibitor selected from sodium butyrate, or a prodrug thereof, suberoylanilide hydroxamic acid (SAHA), sodium valproate and trichostatin A (TSA) as a combined preparation for simultaneous, sequential or separate use in therapy. A third aspect of the invention relates to a method for treating a proliferative disorder, said method comprising simultaneously, sequentially or separately administering roscovitine, or a pharmaceutically acceptable salt thereof, and a HDAC inhibitor selected from sodium butyrate, or a prodrug thereof, suberoylanilide hydroxamic acid (SAHA), sodium valproate and trichostatin A (TSA) to a subject.	12-10-2009